The purpose of this guidance is to identify the types of decision support software functionalities that: (1) do not meet the definition of a device as amended by the Cures Act; (2) may meet the definition of a device but for which FDA does not intend to enforce compliance with applicable requirements of the FD&C Act, including, but not limited to, premarket clearance and premarket approval requirements; and (3) FDA intends to focus its regulatory oversight on.
News & Trends
Procurar
Recentes
- A Formiventos está novamente no ranking das Top 5% melhores PME de Portugal
- Electronic Submission Template for Premarket Approval Applications (PMAs)
- MDSAP Technical Review and Recognition Decision Procedure
- Essential Principles and Content of Predetermined Change Control Plans. Final Document
- Report on the International Active Pharmaceutical Ingredient Inspection Programme 2017 – 2024
- GMP and GDP Question and Answer Guide Version 03 published by ECA
- Guideline on good pharmacovigilance practices (GVP) Module III – Pharmacovigilance inspections (Rev 2)
- Publication of COMBINE Project 2 Sponsors’ guide on safety reporting in combined studies